BRA
APTO

Blue Rock Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Blue Rock Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-136
Closed -$367K – 102
2020
Q3 		$367K Buy
+136
New +$339K 0.32% 76

Other funds holding APTO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Blue Rock Advisors's APTO Position: Q4 2020 in Review

Blue Rock Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q4 2020, closing a stake of 136 shares — an estimated $367K sold.

Blue Rock Advisors first reported a position in APTO in Q3 2020 and held it in 1 quarter. The position peaked at $367K in Q3 2020. 65 funds tracked by Wall St. Rank hold APTO as of Q4 2020.

  • Blue Rock Advisors reported no remaining Aptose Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 136 Aptose Biosciences, Inc. shares in Q4 2020, an estimated $367K.
  • Blue Rock Advisors first reported a position in Aptose Biosciences, Inc. in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's Aptose Biosciences, Inc. position peaked at $367K in Q3 2020.
  • 65 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.